303 related articles for article (PubMed ID: 24224472)
1. Neuroprotective and symptomatic effects of targeting group III mGlu receptors in neurodegenerative disease.
Williams CJ; Dexter DT
J Neurochem; 2014 Apr; 129(1):4-20. PubMed ID: 24224472
[TBL] [Abstract][Full Text] [Related]
2. Metabotropic glutamate receptors as therapeutic targets in Parkinson's disease: An update from the last 5 years of research.
Litim N; Morissette M; Di Paolo T
Neuropharmacology; 2017 Mar; 115():166-179. PubMed ID: 27055772
[TBL] [Abstract][Full Text] [Related]
3. The impact of metabotropic glutamate receptors into active neurodegenerative processes: A "dark side" in the development of new symptomatic treatments for neurologic and psychiatric disorders.
Bruno V; Caraci F; Copani A; Matrisciano F; Nicoletti F; Battaglia G
Neuropharmacology; 2017 Mar; 115():180-192. PubMed ID: 27140693
[TBL] [Abstract][Full Text] [Related]
4. Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease.
Austin PJ; Betts MJ; Broadstock M; O'Neill MJ; Mitchell SN; Duty S
Br J Pharmacol; 2010 Aug; 160(7):1741-53. PubMed ID: 20649576
[TBL] [Abstract][Full Text] [Related]
5. Activation of microglial group III metabotropic glutamate receptors protects neurons against microglial neurotoxicity.
Taylor DL; Diemel LT; Pocock JM
J Neurosci; 2003 Mar; 23(6):2150-60. PubMed ID: 12657674
[TBL] [Abstract][Full Text] [Related]
6. Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs.
Bruno V; Battaglia G; Copani A; D'Onofrio M; Di Iorio P; De Blasi A; Melchiorri D; Flor PJ; Nicoletti F
J Cereb Blood Flow Metab; 2001 Sep; 21(9):1013-33. PubMed ID: 11524608
[TBL] [Abstract][Full Text] [Related]
7. Metabotropic glutamate receptors: potential drug targets for the treatment of schizophrenia.
Chavez-Noriega LE; Schaffhauser H; Campbell UC
Curr Drug Targets CNS Neurol Disord; 2002 Jun; 1(3):261-81. PubMed ID: 12769619
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotection by metabotropic glutamate receptor agonists on kainate-induced degeneration of motor neurons in spinal cord slices from adult rat.
Pizzi M; Benarese M; Boroni F; Goffi F; Valerio A; Spano PF
Neuropharmacology; 2000 Mar; 39(5):903-10. PubMed ID: 10699456
[TBL] [Abstract][Full Text] [Related]
9. Group III and subtype 4 metabotropic glutamate receptor agonists: discovery and pathophysiological applications in Parkinson's disease.
Amalric M; Lopez S; Goudet C; Fisone G; Battaglia G; Nicoletti F; Pin JP; Acher FC
Neuropharmacology; 2013 Mar; 66():53-64. PubMed ID: 22664304
[TBL] [Abstract][Full Text] [Related]
10. Metabotropic Glutamate Receptors in Glial Cells: A New Potential Target for Neuroprotection?
Spampinato SF; Copani A; Nicoletti F; Sortino MA; Caraci F
Front Mol Neurosci; 2018; 11():414. PubMed ID: 30483053
[TBL] [Abstract][Full Text] [Related]
11. Actions of Group I and Group II metabotropic glutamate receptor ligands on 5-hydroxytryptamine release in the rat cerebral cortex in vivo: differential roles in the regulation of central serotonergic neurotransmission.
Lee JJ; Croucher MJ
Neuroscience; 2003; 117(3):671-9. PubMed ID: 12617971
[TBL] [Abstract][Full Text] [Related]
12. Metabotropic glutamate receptors as targets for multipotential treatment of neurological disorders.
Byrnes KR; Loane DJ; Faden AI
Neurotherapeutics; 2009 Jan; 6(1):94-107. PubMed ID: 19110202
[TBL] [Abstract][Full Text] [Related]
13. Activation of Group II/III metabotropic glutamate receptors attenuates LPS-induced astroglial neurotoxicity via promoting glutamate uptake.
Zhou F; Yao HH; Wu JY; Yang YJ; Ding JH; Zhang J; Hu G
J Neurosci Res; 2006 Aug; 84(2):268-77. PubMed ID: 16752416
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease.
Duty S
Br J Pharmacol; 2010 Sep; 161(2):271-87. PubMed ID: 20735415
[TBL] [Abstract][Full Text] [Related]
15. Amyloid-beta neurotoxicity and clearance are both regulated by glial group II metabotropic glutamate receptors.
Durand D; Carniglia L; Turati J; Ramírez D; Saba J; Caruso C; Lasaga M
Neuropharmacology; 2017 Sep; 123():274-286. PubMed ID: 28495373
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective actions of novel and potent ligands of group I and group II metabotropic glutamate receptors.
Kingston AE; O'Neill MJ; Bond A; Bruno V; Battaglia G; Nicoletti F; Harris JR; Clark BP; Monn JA; Lodge D; Schoepp DD
Ann N Y Acad Sci; 1999; 890():438-49. PubMed ID: 10668448
[TBL] [Abstract][Full Text] [Related]
17. Metabotropic glutamate autoreceptors of the mGlu(5) subtype positively modulate neuronal glutamate release in the rat forebrain in vitro.
Thomas LS; Jane DE; Harris JR; Croucher MJ
Neuropharmacology; 2000 Jul; 39(9):1554-66. PubMed ID: 10854900
[TBL] [Abstract][Full Text] [Related]
18. Functional interaction of metabotropic glutamate receptor 5 and NMDA-receptor by a metabotropic glutamate receptor 5 positive allosteric modulator.
Rosenbrock H; Kramer G; Hobson S; Koros E; Grundl M; Grauert M; Reymann KG; Schröder UH
Eur J Pharmacol; 2010 Aug; 639(1-3):40-6. PubMed ID: 20371241
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective activity of metabotropic glutamate receptor ligands.
Flor PJ; Battaglia G; Nicoletti F; Gasparini F; Bruno V
Adv Exp Med Biol; 2002; 513():197-223. PubMed ID: 12575822
[TBL] [Abstract][Full Text] [Related]
20. Changes in rat serum corticosterone after treatment with metabotropic glutamate receptor agonists or antagonists.
Johnson MP; Kelly G; Chamberlain M
J Neuroendocrinol; 2001 Aug; 13(8):670-7. PubMed ID: 11489083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
